Completed PHASE2 INTERVENTIONAL NCT00274963

Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Treatment of Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) WITH Bendamustine / Mitoxantrone (BM)

Sponsor: German CLL Study Group

Interventions bendamustine hydrochloride mitoxantrone hydrochloride

Updated 6 times since 2017 Last updated: May 9, 2018 Started: Oct 31, 2004 Primary completion: Nov 30, 2007 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Lymphocytic Leukemia, this trial is completed. The trial is conducted by German CLL Study Group and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

German CLL Study Group

Data source: German CLL Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Saarow, Germany , Berlin, Germany , Cologne, Germany , Halle, Germany , Hamm, Germany , Koblenz, Germany , Krefeld, Germany , Kronach, Germany , Neuss, Germany , Oldenburg, Germany and 2 more locations